PT1776957T - Uso de vetores herpes para terapia tumoral - Google Patents

Uso de vetores herpes para terapia tumoral

Info

Publication number
PT1776957T
PT1776957T PT60216975T PT06021697T PT1776957T PT 1776957 T PT1776957 T PT 1776957T PT 60216975 T PT60216975 T PT 60216975T PT 06021697 T PT06021697 T PT 06021697T PT 1776957 T PT1776957 T PT 1776957T
Authority
PT
Portugal
Prior art keywords
tumor
cells
patient
immune response
cell type
Prior art date
Application number
PT60216975T
Other languages
English (en)
Inventor
D Rabkin Samuel
Toda Masahiro
L Martuza Robert
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1776957(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of PT1776957T publication Critical patent/PT1776957T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT60216975T 1997-08-12 1998-08-12 Uso de vetores herpes para terapia tumoral PT1776957T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5514297P 1997-08-12 1997-08-12
US09/064,174 US6379674B1 (en) 1997-08-12 1998-04-22 Use of herpes vectors for tumor therapy

Publications (1)

Publication Number Publication Date
PT1776957T true PT1776957T (pt) 2017-06-12

Family

ID=26733894

Family Applications (1)

Application Number Title Priority Date Filing Date
PT60216975T PT1776957T (pt) 1997-08-12 1998-08-12 Uso de vetores herpes para terapia tumoral

Country Status (12)

Country Link
US (5) US6379674B1 (pt)
EP (2) EP1776957B1 (pt)
JP (2) JP5078195B2 (pt)
AT (1) ATE342724T1 (pt)
AU (1) AU8824998A (pt)
CA (1) CA2301327C (pt)
DE (1) DE69836219T2 (pt)
ES (2) ES2276470T3 (pt)
HK (1) HK1028560A1 (pt)
LU (1) LUC00032I2 (pt)
PT (1) PT1776957T (pt)
WO (1) WO1999007394A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
WO2000040734A1 (en) * 1998-12-31 2000-07-13 Arch Development Corporation Recombinant herpes simplex virus useful for treating neoplastic disease
AU6120600A (en) * 1999-06-08 2000-12-28 Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
WO2001045737A2 (en) * 1999-12-22 2001-06-28 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
AU2695101A (en) * 2000-01-21 2001-07-31 Biovex Ltd Virus strains
CA2441663C (en) 2001-03-27 2013-01-22 Medigene, Inc. Viral vectors and their use in therapeutic methods
JP2004529158A (ja) * 2001-05-02 2004-09-24 ラモツト・アツト・テル−アビブ・ユニバーシテイ・リミテツド 混成殺腫瘍ヘルペスウイルスベクター
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
EP1487983A4 (en) * 2002-03-01 2007-08-15 Sloan Kettering Inst Cancer PREVENTING THE REPEAT AND METASTASIS OF CANCER
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US8216564B2 (en) * 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
JP5522884B2 (ja) 2004-03-31 2014-06-18 具紀 藤堂 ウイルス療法の抗癌作用増強剤、癌の予防または治療方法
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
WO2009052426A2 (en) * 2007-10-17 2009-04-23 The Ohio State University Oncolytic virus
KR100905419B1 (ko) 2008-09-11 2009-07-02 연세대학교 산학협력단 세스퀴테르펜 유도체의 용도
WO2010054379A2 (en) 2008-11-10 2010-05-14 The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
PL2753355T3 (pl) 2011-09-08 2019-04-30 Benevir Biopharm Inc Onkolityczny wirus opryszczki pospolitej i jego zastosowania lecznicze
KR102549746B1 (ko) 2014-12-18 2023-07-03 암젠 인크 안정한 동결된 단순 포진 바이러스 제제
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
WO2017013421A1 (en) 2015-07-20 2017-01-26 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
JP7038065B2 (ja) 2016-01-08 2022-03-17 レプリミュン リミテッド 腫瘍溶解性ウイルス株
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
ES2882538T3 (es) * 2016-05-30 2021-12-02 Astellas Pharma Inc Nuevos virus de la vaccinia modificados por ingeniería genética
US20190169253A1 (en) * 2016-08-01 2019-06-06 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
AU2018235944B2 (en) 2017-03-15 2024-01-04 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
UY37829A (es) 2017-08-03 2019-01-31 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
JP2020530003A (ja) 2017-08-07 2020-10-15 アムジェン インコーポレイテッド 抗ｐｄ−ｌ１抗体及び腫瘍溶解性ウイルスでの、肝転移を伴う三種陰性乳がん又は結腸直腸がんの処置
EP4403175A3 (en) 2017-09-08 2024-10-02 Amgen Inc. Inhibitors of kras g12c and methods of using the same
ES2941740T3 (es) 2018-01-12 2023-05-25 Amgen Inc Anticuerpos anti-PD-1 y métodos de tratamiento
CN108635380A (zh) * 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
AU2019351255A1 (en) 2018-09-26 2021-04-29 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
AR117547A1 (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas
EP3935182A1 (en) 2019-03-05 2022-01-12 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
EP4314028A1 (en) * 2021-04-02 2024-02-07 Krystal Biotech, Inc. Viral vectors for cancer therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001828A (nl) 1990-08-15 1992-03-02 Centraal Diergeneeskundig Inst Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde.
WO1992014821A2 (en) 1990-10-25 1992-09-03 Massachusetts Institute Of Technology Nestin expression as an indicator of neuroepithelial tumors
WO1993019591A1 (en) * 1992-03-31 1993-10-14 Arch Development Corporation Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US5639656A (en) * 1994-03-31 1997-06-17 Medical College Of Hampton Road Antibodies reactive with biological markers of benign prostate hyperplasia
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US6699468B1 (en) * 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
JP3822261B2 (ja) * 1994-09-09 2006-09-13 財団法人癌研究会 癌の遺伝子治療剤
GB9511101D0 (en) 1995-06-01 1995-07-26 British Tech Group Magnetic coil
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
CA2441663C (en) * 2001-03-27 2013-01-22 Medigene, Inc. Viral vectors and their use in therapeutic methods

Also Published As

Publication number Publication date
AU8824998A (en) 1999-03-01
WO1999007394A1 (en) 1999-02-18
US20130224243A1 (en) 2013-08-29
JP5078195B2 (ja) 2012-11-21
EP1776957A3 (en) 2009-06-24
ES2276470T3 (es) 2007-06-16
US9827307B2 (en) 2017-11-28
EP1776957B1 (en) 2017-03-01
ATE342724T1 (de) 2006-11-15
US20020127246A1 (en) 2002-09-12
DE69836219D1 (de) 2006-11-30
ES2627764T3 (es) 2017-07-31
EP1776957A2 (en) 2007-04-25
CA2301327A1 (en) 1999-02-18
DE69836219T2 (de) 2007-08-23
HK1028560A1 (en) 2001-02-23
LUC00032I2 (pt) 2017-10-11
CA2301327C (en) 2011-06-14
JP2001513508A (ja) 2001-09-04
EP1003533A1 (en) 2000-05-31
LUC00032I1 (pt) 2017-08-10
US20090053178A1 (en) 2009-02-26
US20050232907A1 (en) 2005-10-20
US8361978B2 (en) 2013-01-29
US6379674B1 (en) 2002-04-30
JP2012067114A (ja) 2012-04-05
EP1003533B1 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
LUC00032I1 (pt)
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
HUT72558A (en) Defective adenovirus vectors and use thereof in gene therapy
EP0584266A4 (en) KARCINOEMBRYONAL ANTIGENT EXPECTING RECOMBINANT VIRUSES AND METHODS OF USE.
WO1996003997A3 (en) Treatment of cancer using hsv mutant
EP0623020A4 (en) PYROPHEOPHORBIDES AND THEIR USE IN PHOTODYNAMIC THERAPY.
BRPI0107737B1 (pt) vírus do herpes simplex 1 (hsv1), uso do hsv1, e, composição farmacêutica
AU4283389A (en) Modified viral glycoproteins, diagnostic and therapeutic uses therefore
GB9415167D0 (en) Improvements relating to cancer therapy
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
AU2905199A (en) Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
AU1927797A (en) Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
ZA941426B (en) Recombinant viruses and their use in gene therapy
GR3031354T3 (en) Soluble interferon -receptor, its preparation and use.
GB9601640D0 (en) Ligand directed enzyme prodrug therapy
EP0876507A4 (en) CONTROL AND CONTROL OF THE EXPRESSION OF THE PROTEIN PHOSPHATASE 2C-PP2C-ALPHA IN TUMOR CELLS IN TUMOR THERAPY, PREVENTION AND DETERMINATION
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
EP0828005A3 (en) Apoptotic agents for tumor cells of the nervous system
EP0373658A3 (en) Use of quinoline derivatives in treating cancer
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IL112994A0 (en) Recombinant viruses, their preparation and their use in gene therapy
Newman Regenerative abysses, reflective myopias, and the assassination of Oscar Romero: A Turnerian analysis of social drama and the development of anti-systemic religious paradigms during the Salvadoran rebellion
刘言寿 et al. SCAPULOHUMERAL PERIARTHRITIS TREATED WITH WATER-ACUPUNCTURE PRINCIPALLY